Komori
KYORIN Pharmaceutical (4569) · PolicyReframed

Capital Policy Balancing Growth Investment and Shareholder Returns

First written in FY2017. 5 of 9 entries say "Restated". Latest entry: FY2026.

9entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019-Q2 – FY2019RestatedFY20242017: 120172018: 320182019: 220192020: 020202021: 020212022: 020222023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Capital allocation policy balancing future investment and shareholder dividendsA theme 469 companies write about · 0 as a headwind · 471 as a tailwind

KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2026, 3 years after the typical company in this theme (2023).

6 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 473 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026ReframedAnnual report

    「We will prioritize investment to expand our pipeline for sustainable growth from Stage 3 onward, consider increasing the dividend in light of business performance and cash flow, while securing an annual dividend of ¥25 per share.」

    In Stage 2, the company has organized its existing policy of balancing growth investment and shareholder returns into a policy of prioritizing pipeline expansion investment while securing dividends.
  2. FY2024RestatedAnnual report

    「Our basic capital policy is to improve capital efficiency through growth investment and shareholder returns while maintaining a sound financial base and remaining constantly mindful of the cost of capital and return on capital.」

    The company continues its policy of improving capital efficiency through growth investment and shareholder returns while remaining mindful of the cost of capital and return on capital.
  3. FY2023ReframedAnnual report

    「Our basic capital policy is to improve capital efficiency through growth investment and shareholder returns while maintaining a sound financial base and remaining constantly mindful of the cost of capital and return on capital.」

    The company has explicitly added a constant focus on the cost of capital and return on capital to its existing policy of improving capital efficiency.
  4. FY2019RestatedAnnual report

    「Our basic policy is to improve capital efficiency through growth investment and shareholder returns while maintaining a sound financial base」

    The company continues its policy of improving capital efficiency through growth investment and shareholder returns while maintaining a sound financial base.
  5. FY2019-Q3RestatedAnnual report

    「Regarding capital policy, we will seek to improve capital efficiency through growth investment and shareholder returns while maintaining a sound financial base.」

    The company continues its policy of improving capital efficiency through growth investment and shareholder returns while maintaining a sound financial base.
  6. FY2019-Q2RestatedAnnual report

    「Regarding capital policy, we will seek to improve capital efficiency through growth investment and shareholder returns while maintaining a sound financial base.」

    The company continues its policy of improving capital efficiency through growth investment and shareholder returns while maintaining a sound financial base.
  7. FY2019-Q1ReframedAnnual report

    「Regarding capital policy, we will seek to improve capital efficiency through growth investment and shareholder returns while maintaining a sound financial base.」

    The company has clarified its existing policy of balancing growth investment and shareholder returns as a policy centered on improving capital efficiency.
  8. FY2018RestatedAnnual report

    「While maintaining a sound financial base, we will pursue a capital policy that balances growth investment and shareholder returns.」

    The company has reaffirmed its policy of balancing growth investment and shareholder returns while maintaining a sound financial base.
  9. FY2017First statedAnnual report

    「While maintaining a sound financial base, we will pursue a capital policy that balances growth investment and shareholder returns.」

    The Group aims to balance growth investment and shareholder returns while maintaining a sound financial base.
Moved together

"Decline in Upfront License Fees and Royalty Income" moved the same way as this thread, in the same document, in 3 of its 9 moves.

3222★1234
  1. ★This thread
  2. 1Decline in Upfront License Fees and Royalty Income3×
  3. 2Challenging Domestic Pharmaceutical Business Environment Due to Drug Price Revisions2×
  4. 3Diversifying Business Risk through a Combination of the Prescription Pharmaceutical and Healthcare Businesses2×
  5. 4Driving Transformation by Bringing Together Diverse Knowledge2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.